ADAR1 Capital Management »

Cerevel Therapeutics Hldng I shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Cerevel Therapeutics Hldng I (CERE) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Cerevel Therapeutics Hldng I

Tip: Access up to 7 years of quarterly data

All positions including Cerevel Therapeutics Hldng I held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Cerevel Therapeutics Hldng I by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $6.8M 161k 42.40

More positions owned by ADAR1 Capital Management

Alnylam Pharmaceuticals (ALNY)
Royalty Pharma Shs Class A (RPRX)
Keros Therapeutics (KROS)
Roivant Sciences SHS (ROIV)
Cytokinetics Com New (CYTK)
Arbutus Biopharma (ABUS)
Bridgebio Pharma (BBIO)
Merrimack Pharmaceuticals In Com New (MACK)
Cerevel Therapeutics Hldng I (CERE)
Mirati Therapeutics
Merck & Co (MRK)
Ascendis Pharma A/s Sponsored Adr (ASND)
Immunovant (IMVT)
Viking Therapeutics (VKTX)
Protagonist Therapeutics (PTGX)

View all positions for ADAR1 Capital Management

Top funds holding Cerevel Therapeutics Hldng I

Perceptive Advisors
venBio Select Advisor
Vanguard Group
Paradigm Biocapital Advisors
Balyasny Asset Management
Alpine Associates Management
Baker Bros. Advisors
Alliancebernstein
Millennium Management
Pentwater Capital Management
CNH Partners
Westchester Capital Management
Voloridge Investment Management
Westfield Capital Management Company
T. Rowe Price Associates

View all funds holding Cerevel Therapeutics Hldng I